Peptide · developed by Novo Nordisk
Cagrilintide is a drug administered subcutaneously by pen injector as an adjunct to lifestyle intervention counselling. It is studied in overweight, obesity and type 2 diabetes.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07220759 | Phase 3 | Overweight | Active not recruiting | NVO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
ObesityOverweightType 2 Diabetes
Updated Nov 8, 2026. Something wrong or missing? Report it on the NVO page.
See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVO catalysts and pipeline →